NCT03707028View on ClinicalTrials.gov

A Study to Evaluate Safety, Tolerability, and Efficacy Profile of Rivoceranib With Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 1, 2018

Primary Completion Date

August 24, 2021

Study Completion Date

August 24, 2021

Conditions
Gastric CancerGastroesophageal Junction Adenocarcinoma
Interventions
DRUG

Rivoceranib

Film-coated tablet

DRUG

Paclitaxel

Solution administered intravenously

Trial Locations (1)

05505

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Elevar Therapeutics

INDUSTRY

NCT03707028 - A Study to Evaluate Safety, Tolerability, and Efficacy Profile of Rivoceranib With Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer | Biotech Hunter | Biotech Hunter